It seems as if people should be cautious and if they or their friends and family do not improve in a health condition after taking the prescribed drug , they should ask to be switched to a generic from another manufacturer. At least, always write down the manufacturer of the drug you are taking.
Listing the country of origin will not help if the consumer has no alternative. As it stands today, patients are at the mercy of the insurers’ formularies. If you and your doctor want to prescribe a particular drug, your insurance may not cover it or may only cover the generic version. And, frequently, the low cost generics have active ingredients made outside the US. This will only get worse until Congress puts up money for inspections. Maybe they should charge the Chinese drug companies for teh efforts needed to monitor them.
The authors comments referring to the President’s comments about being tough on China in trade were completely unnecessary. The focus on the tariffs are at the borders of the US, not the controls such as the FDA auditing a Chinese drug manufacturer. However, the fact that auditors from the FDA were placed in a conference room until information about who they were could be verified is an issue. Such actions should incur a temporary suspension for the importing of those products. Such rules should be universal regardless the location of the production of the drug (domicile / non domicile).
Comments are closed.